breast cancer

Lukangsatuzumab: A Domestic TROP2 ADC Cancer Treatment Star, Multiple Phase III Studies Top International Journals

by
Lukangsatuzumab: A Domestic TROP2 ADC Cancer Treatment Star, Multiple Phase III Studies Top International Journals

The medical community welcomes a new “weapon” against cancer, as a domestic innovative drug demonstrates outstanding performance in the treatment of lung cancer and breast cancer, bringing new hope to advanced patients.At the 2025 European Society for Medical Oncology (ESMO) annual meeting, a domestically developed innovative antibody-drug conjugate—Lukangsatuzumab (Sac-TMT, Jiatai Lai®)—announced multiple Phase III clinical … Read more

China’s Original HER2 ADC Botuzumab (Shutai Lai®) Prescriptions Launched, Opening a New Chapter in HER2 Positive Breast Cancer Treatment

by
China's Original HER2 ADC Botuzumab (Shutai Lai®) Prescriptions Launched, Opening a New Chapter in HER2 Positive Breast Cancer Treatment

Introduction The field of anti-tumor treatment in China has reached a significant milestone—the first domestically developed HER2 antibody-drug conjugate (ADC) Botuzumab (Shutai Lai®) for the treatment of HER2 positive breast cancer, which can be widely used in second-line and above therapies, has been prescribed in multiple top hospitals across the country.This marks the official entry … Read more

Which Patients Can Benefit More from ADC Treatment?

by
Which Patients Can Benefit More from ADC Treatment?

Introduction In the field of cancer treatment, antibody-drug conjugates (ADCs) are hailed as “biological missiles” that can precisely deliver high concentrations of chemotherapy drugs to tumor cells, enhancing efficacy while reducing damage to normal tissues. Among them, trastuzumab deruxtecan (T-DXd, also known as DS-8201), which targets the HER2 protein, has become a significant breakthrough in … Read more

Overview of Six Major Breast Cancer ADCs Launched in China

by
Overview of Six Major Breast Cancer ADCs Launched in China

Introduction Breast cancer is one of the most common malignant tumors among women worldwide and is also a leading cause of cancer-related deaths. According to the data released in the “2022 Global Cancer Statistics Report”, there were approximately 20 million new cancer cases globally, with women accounting for 9.7 million, and breast cancer accounting for … Read more

Biomarkers for ADCs: IHC and Beyond

by
Biomarkers for ADCs: IHC and Beyond

WCLC 2025 has numerous topics on ADCs, and in the spirit of learning, I am joining the discussion. Let’s see how ADCs are viewed in the field of lung cancer, a leading area in cancer treatment, and what research directions exist for ADCs in this domain.Biomarkers for ADCs: IHC and Beyond, presented by Dr. Sewanti … Read more

Exosome Aptamer Sensors for Staging Breast Cancer

by
Exosome Aptamer Sensors for Staging Breast Cancer

Accurate diagnosis and staging of breast cancer are crucial for guiding clinical treatment strategies and predicting patient survival outcomes. Current clinical methods face limitations in detecting small tumors and micrometastases, such as imaging techniques; although biopsy remains the gold standard, its invasiveness makes it unsuitable for repeated use. Liquid biopsy is a promising solution that … Read more

Antibody–Drug Conjugates for Breast Cancer Treatment

by
Antibody–Drug Conjugates for Breast Cancer Treatment

Let’s take a look at the recent hot topic of ADC drugs, and systematically learn about the review published in CancersAntibody–Drug Conjugates for the Treatment of Breast Cancer. Abstract Currently, besides endocrine therapy and targeted drugs, metastatic breast cancer (BC) commonly uses chemotherapy as a treatment method. However, the lack of tumor specificity and toxicity … Read more

Available ADC Drugs for Breast Cancer Patients

by
Available ADC Drugs for Breast Cancer Patients

IntroductionIn the field of breast cancer treatment, antibody-drug conjugates (ADC) are gradually becoming an important therapeutic approach.ADC drugs are a new type of cancer treatment that combines the targeting capability of antibodies with the potent killing power of chemotherapy drugs, allowing for precise delivery of chemotherapy agents to cancer cells, thereby improving efficacy and reducing … Read more

How to Address 8 Common Adverse Reactions of ADC Drugs?

by

With the recent approvals of Trastuzumab emtansine (T-DM1) and Gemtuzumab ozogamicin in China, the review of Trastuzumab deruxtecan (T-DXd, DS-8201) is progressing steadily, marking the arrival of a “future” where antibody-drug conjugates (ADCs) greatly benefit breast cancer patients in China. ADCs achieve “precision targeting” of tumors and are referred to as “magic bullets,” changing the … Read more

Management of Adverse Reactions to ADC Drugs in Breast Cancer

by
Management of Adverse Reactions to ADC Drugs in Breast Cancer

Antibody-drug conjugates (ADC) are a new class of targeted drugs composed of monoclonal antibodies (mAbs), cytotoxic drugs, and linkers that connect the two. They utilize the targeting capability of antibodies to selectively deliver cytotoxic molecules to tumor cells, exerting anti-cancer effects while avoiding impacts on healthy cells. ADC drugs have rapidly developed in the field … Read more